Preexisting antibody assays for gene therapy: Considerations on patient selection cutoffs and companion diagnostic requirements

Manuela Braun(Bayer (Germany)), Mark Milton(Novartis (United States)), Vibha Jawa(Bristol-Myers Squibb (Germany)), Daisy Yuill(The Francis Crick Institute), Louis Christodoulou(UCB Pharma (United Kingdom)), Nicole L. Miller, Tong‐Yuan Yang(Janssen (United States)), Boris Gorovits(Pfizer (United States)), Edit Tarcsa(Massachusetts Academy of Math and Science at WPI), Fraser McBlane(Novartis (Switzerland)), Claudia Lange(Bayer (Germany)), Philipp Schatz(AstraZeneca (Sweden)), Wibke Lembke, Brian Long(BioMarin (United States)), Johannes Stanta

Molecular Therapy — Methods & Clinical Development

February 20, 2024

10.1016/j.omtm.2024.101217

Cited by 25

Related Papers

Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper

|Molecular Therapy — Methods & Clinical Development|2022|113

Geographic and Ethnic Heterogeneity of Germline <i>BRCA1</i> or <i>BRCA2</i> Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial

|Journal of Clinical Oncology|2020|73

2020 White Paper on Recent Issues in Bioanalysis: Vaccine Assay Validation, qPCR Assay Validation, QC for CAR-T Flow Cytometry, NAb Assay Harmonization and ELISpot Validation ( <u>Part 3</u> –Recommendations on Immunogenicity Assay Strategies, NAb Assays, Biosimilars and FDA/EMA Immunogenicity Guidance/Guideline, Gene & Cell Therapy and Vaccine Assays)

|Bioanalysis|2021|60

Generation and characterization of ABT-981, a dual variable domain immunoglobulin (DVD-Ig<sup>TM</sup>) molecule that specifically and potently neutralizes both IL-1α and IL-1β

|mAbs|2015|57

Assay format diversity in pre-clinical immunogenicity risk assessment: Toward a possible harmonization of antigenicity assays

|mAbs|2021|57